Karyopharm Therapeutics Inc. (NasdaqGS: KPTI)
Karyopharm Therapeutics Inc.
Stock Symbol: NasdaqGS: KPTI
Class Period Start: 03/02/2017
Class Period End (inclusive): 03/02/2017
Filing Deadline: 09/23/2019
Court: District of Massachusetts
The law firm of Barbuto & Johansson, P.A. and Director of Client Relations Neil Rothstein, Esq. remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against Karyopharm Therapeutics Inc. (NasdaqGS: KPTI), if they purchased the Company’s shares issued in connection with its April 2017 or May 2018 public offering or between March 2, 2017 and February 22, 2019, inclusive (the “Class Period”).
Karyopharm and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 22, 2019, the Federal Drug Administration (“FDA”) reported serious concerns with the Company’s drug, selinexor. Specifically, the FDA concluded that, contrary to the Company’s prior assurances, “[t]reatment with selinexor is associated with significant toxicity” with “limited efficacy.”
On this news, the price of Karyopharm’s shares plummeted.
If you purchased shares of Karyopharm and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, please contact one of our attorneys. Call the firm today at (561) 444-7980 and/or fill out the form to the right.
The case is Allegheny County Employees’ Retirement System v. Karyopharm Therapeutics Inc., 1:19-cv-11597. Click here to read full case complaint.